secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pharma-Bio Serv, Inc. (PBSV)
CIK:        0001304161
Form:       8-K
Filed at:   2022-09-14T23:59:59+00:00
Accession:  0001654954-22-012521
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pharma-Bio Serv Q3 revenue $4.8M, net income $0.3M down $2M YoY on SBA loan forgiveness
--------------------------------------------------------------------------------

- Revenue for Q3 ended July 31, 2022: $4.8M, down $0.2M YoY; 9-month revenue $14.8M, up $0.2M.
- Net income Q3: $0.3M vs. $2.3M prior year; prior year included $2.0M SBA loan forgiveness gain.
- Repurchased 10,400 shares in Q3 and 81,303 in first nine months; 1,551,943 shares remain authorized.
- CEO notes revenue growth in U.S. and European consulting markets, citing expansion opportunities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1304161/000165495422012521/0001654954-22-012521-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1304161/000165495422012521/pbsv_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-012521

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer